📗 Cite This Artifact
AAIC 2026: Early Detection and Preclinical AD
Early Detection and Preclinical Alzheimer's Disease at AAIC 2026
AAIC 2026 showcased significant advances in early detection of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), focusing on identifying pathological changes before clinical symptoms emerge. The shift toward preclinical intervention represents a fundamental change in AD research and clinical practice.
Conceptual Framework
Preclinical AD Staging
The preclinical AD framework continues to evolve[@sperling2011]:
- Stage 1: Amyloid positivity without neurodegeneration or cognitive impairment
- Stage 2: Amyloid + neurodegeneration (AD signature region atrophy, FDG hypometabolism, or [tau](/proteins/tau) PET positivity)
- Stage 3: Amyloid + neurodegeneration + subtle cognitive changes
Biomarker Staging Models
New integrated biomarker approaches:
- AT(N) classification: Amyloid (A), Tau (T), Neurodegeneration (N)
- Blood-based biomarkers: Adding AT(Blood) to the framework
- Dynamic biomarkers: Rate of change as predictive markers
Blood-Based Biomarker Screening
Population-Level Screening
Advances in blood biomarker implementation[@schindler2024]:
- Primary care integration: Feasibility studies in community settings
- At-risk populations: Screening in individuals with family history, cardiovascular disease, or diabetes
- Cost-effectiveness: Modeling for population screening programs
Implementation Challenges
Practical considerations discussed at AAIC 2026:
Early Detection and Preclinical Alzheimer's Disease at AAIC 2026
AAIC 2026 showcased significant advances in early detection of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), focusing on identifying pathological changes before clinical symptoms emerge. The shift toward preclinical intervention represents a fundamental change in AD research and clinical practice.
Conceptual Framework
Preclinical AD Staging
The preclinical AD framework continues to evolve[@sperling2011]:
- Stage 1: Amyloid positivity without neurodegeneration or cognitive impairment
- Stage 2: Amyloid + neurodegeneration (AD signature region atrophy, FDG hypometabolism, or [tau](/proteins/tau) PET positivity)
- Stage 3: Amyloid + neurodegeneration + subtle cognitive changes
Biomarker Staging Models
New integrated biomarker approaches:
- AT(N) classification: Amyloid (A), Tau (T), Neurodegeneration (N)
- Blood-based biomarkers: Adding AT(Blood) to the framework
- Dynamic biomarkers: Rate of change as predictive markers
Blood-Based Biomarker Screening
Population-Level Screening
Advances in blood biomarker implementation[@schindler2024]:
- Primary care integration: Feasibility studies in community settings
- At-risk populations: Screening in individuals with family history, cardiovascular disease, or diabetes
- Cost-effectiveness: Modeling for population screening programs
Implementation Challenges
Practical considerations discussed at AAIC 2026:
- Assay standardization across laboratories
- Cut-point determination for clinical use
- Disclosure protocols for positive results
Sensitive Detection Methods
Ultra-Sensitive Assays
Single-molecule array (Simoa) and other ultrasensitive platforms:
- Detecting [amyloid-beta](/proteins/amyloid-beta) at concentrations 100x lower than standard assays
- [p-Tau217](/biomarkers/p-tau-217) elevation in cognitively normal individuals with amyloid positivity
- [GFAP](/entities/gfap) as early marker of astrocyte reactivity
Multimodal Screening
Combining blood biomarkers with other assessments:
- Blood + genetic testing ([APOE](/proteins/apoe) genotyping)
- Blood + digital biomarkers
- Blood + brief cognitive assessments
Cognitive Precursors
Subtle Cognitive Changes
Detecting earliest cognitive manifestations[@bondi2022]:
- Preclinical Cognitive Impairment: Deficits detectable with sensitive neuropsychological tests
- Objective Subtle Cognitive Difficulties (Obj-SCD): Validated assessment approaches
- Cognitive reserve effects: Understanding resilience to pathology
Digital Biomarkers
Technology-enabled cognitive assessment:
- Smartphone-based cognitive testing
- Wearable sensor data for behavioral changes
- Voice analysis for language alterations
Neuroimaging in Early Detection
Amyloid PET Screening
Utilizing PET for early detection:
- Centiloid scale standardization
- Low-dose protocols for screening
- Visual read standardization
Tau PET Sensitivity
Early tau detection advances:
- p-Tau231 as preclinical marker
- [Entorhinal cortex](/brain-regions/entorhinal-cortex) tau as earliest detectable pathology
- Tau spreading patterns in preclinical stages
MRI Markers
Structural MRI in preclinical AD:
- Hippocampal atrophy rates
- Default mode network connectivity changes
- White matter microstructural changes
Risk Prediction Models
Genetic Risk
Polygenic risk scores for AD[@karch2022]:
- Combined APOE and non-APOE genetic variants
- Risk stratification for prevention trials
- Interaction with lifestyle factors
Composite Risk Scores
Integrating multiple risk factors:
- Demographic (age, sex, education)
- Genetic (APOE, polygenic risk)
- Biomarker (fluid, imaging)
- Lifestyle (physical activity, diet, cardiovascular)
Prevention Trial Updates
Enrollment Strategies
Recruitment for preclinical AD trials:
- Blood biomarker-based screening efficiency
- Family history enrichment strategies
- Diverse population recruitment
Primary Prevention Trials
Trials targeting amyloid removal in preclinical populations:
- Anti-amyloid antibodies in cognitively normal amyloid-positive individuals
- Outcome measures for prevention trials
- Ethical considerations in presymptomatic intervention
Clinical Implications
Diagnostic Criteria Updates
Recent revisions to AD diagnostic criteria:
- NIA-AA criteria for preclinical AD
- IWG criteria for presymptomatic AD
- Implementation in clinical practice
Clinical Practice Guidelines
Recommendations for early detection:
- When to offer biomarker testing
- Counseling for individuals with preclinical AD
- Monitoring recommendations
Future Directions
Key areas for future research:
Overview
This page provides information about AAIC 2026: Early Detection and Preclinical AD.
See Also
- [NeuroWiki Home](/home)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | events-aaic-2026-early-detection |
| kg_node_id | None |
| entity_type | event |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-3d7b00c96d0e |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'events-aaic-2026-early-detection'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-events-aaic-2026-early-detection?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[AAIC 2026: Early Detection and Preclinical AD](http://scidex.ai/artifact/wiki-events-aaic-2026-early-detection)
http://scidex.ai/artifact/wiki-events-aaic-2026-early-detection